Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV Infection
Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV Infection
The primary objectives of the study are to evaluate the safety, tolerability, and efficacy of
 voxilaprevir (VOX) plus sofosbuvir/velpatasvir (SOF/VEL) fixed dose combination (FDC) in
 adults with chronic non genotype 1 hepatitis C virus (HCV) infection.
Key Inclusion Criteria:

 -  Individuals with chronic HCV infection

 -  HCV RNA ≥10^4 IU/mL at screening

 -  HCV genotypes 2, 3, 4, 5, or 6

 -  Cirrhosis determination; a liver biopsy may be required

 -  Screening laboratory values within defined thresholds

 -  Use of two contraception methods if female of childbearing potential or sexually
 active male

 Key Exclusion Criteria:

 -  Pregnant or nursing female

 -  Current or prior history of hepatic decompensation

 -  Hepatocellular carcinoma (HCC) or other clinically significant malignancy

 -  Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)

 -  History of clinically significant illness or any other medical disorder that may
 interfere with the individual's treatment, assessment or compliance with the protocol

 NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.